Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2002-02-01
2004-05-25
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S230100, C435S320100, C435S235100, C435S236000
Reexamination Certificate
active
06740324
ABSTRACT:
BACKGROUND
Cytomegaloviruses (CMVs) are common pathogens and are members of the &bgr; subgroup of the herpesvirus family. CMV is a slow replicating, species-specific complex DNA virus found in most mammals. CMV has adopted subtle evolutionary strategies for evading the immune system of an infected host, while disseminating through the host tissues.
The genome (230 kb) of human CMV (HCMV) includes a long and short unique region (UL and US, respectively), each of which is flanked by inverted repetitions. The entire HCMV genome has been sequenced (Chee, M. S., et al. (1990)
Curr. Top. Microbiol. Immunol.
154:125-169) and appears to contain over 200 open reading frames.
One of these open reading frames is referred to as US28, which encodes a protein (also “US28”) that acts as a functional receptor for certain human and viral chemokines (see, e.g., Gao & Murphy, 1994,
J Biol Chem.
269:28539-42). Upon infection of a cell by CMV, US28 is expressed on the surface of the infected cell and becomes capable of responding to chemokines in the environment. Three other open reading frames called US27, UL33 and UL78 encode for proteins having homology to US28 as shown in Table 1 below.
TABLE 1
Exemplary Viral Chemokine Elements
CMV Chemokine
GenBank Acces-
Elements
sion No.
Reference
US27
X17403
Chee et al, 1990, Nature, 344:774
US28
L20501,
Neote et al, 1993, Cell, 72:415-25
AF073831-35
UL33
X53293
Chee et al, 1990, Nature, 344:774
UL78
X17403
Chee et al, 1990, Nature, 344:774
Chemokine receptors such as US28 generally are G protein coupled receptors. Structurally these receptors have seven transmembrane segments that loop in and out of the cell membrane, as well as an intracellular tail that is coupled to a G protein signal transducing molecular complex.
The chemokines themselves constitute a subgroup of a larger class of signaling proteins and have the ability, among other things, to promote cellular migration (Zlotnik et al. (1999)
Crit. Rev. Immunol.
19:1-47). The chemokines generally are divided into four groups based upon the arrangement of certain cysteine residues within the protein that can form disulfide bonds. One class of chemokines is the beta chemokines that are characterized by having two adjacent cysteines; this structure is referred to in shorthand form simply as CC. The beta chemokines are involved in attraction of monocytes and leukocytes. The alpha chemokines, in contrast, have a single amino acid separating the two cysteine residues, and thus their structure is designated as CXC. These chemokines are primarily involved in attracting polymorphonuclear cells. The fractalkines or delta-chemokines constitute a third class of chemokines and tend to be cell bound molecules. The two cysteines in this class are separated by three amino acid residues, a structure designated as CX3C. This class of chemokines are expressed at high levels in the brain; some evidence indicates that the fractalkines are involved in neuron-glial cell interactions (see, e.g., Harrison, et al. (1998)
Proc. Natl. Acad. Sci. U.S.A.
95:10896-10901; and Nishiyori, A. et al. (1998)
FEBS Lett.
429:167-172). The US28 receptor of HCMV is characterized in part by its very strong affinity for fractalkine. The structure of the final class of chemokines is simply referred to as C (also gamma-chemokines), because these chemokines contain only a single N-terminal cysteine involved in a disulfide bond. The chemokine receptors have varying specificity for the different classes of chemokines. Some chemokine receptors can bind chemokines from different classes.
REFERENCES:
patent: 3379729 (1968-04-01), Protiva et al.
patent: 5529771 (1996-06-01), Hooks et al.
patent: 5652133 (1997-07-01), Murphy
patent: 5665362 (1997-09-01), Inglis et al.
patent: 5720957 (1998-02-01), Jones et al.
patent: 5753476 (1998-05-01), Jones et al.
patent: 5756264 (1998-05-01), Schwartz et al.
patent: 5763217 (1998-06-01), Cynader et al.
patent: 5824318 (1998-10-01), Mohr et al.
patent: 5843458 (1998-12-01), Jones
patent: 5846806 (1998-12-01), Jones et al.
patent: 5866136 (1999-02-01), Ramshaw et al.
patent: 5877004 (1999-03-01), Jones et al.
patent: 5908780 (1999-06-01), Jones
patent: 5939320 (1999-08-01), Littman et al.
patent: 5948775 (1999-09-01), Koko et al.
patent: 5965697 (1999-10-01), Czaplewski et al.
patent: 5998160 (1999-12-01), Berens
patent: 6028169 (2000-02-01), Kreider et al.
patent: 6031080 (2000-02-01), Williams et al.
patent: 6033671 (2000-03-01), Frueh et al.
patent: 6034102 (2000-03-01), Aiello
patent: 6051375 (2000-04-01), Rose et al.
patent: 6051428 (2000-04-01), Fong et al.
patent: 6150132 (2000-11-01), Wells et al.
patent: 6420121 (2002-07-01), Nelson et al.
patent: 0277773 (1988-10-01), None
patent: WO 94/11504 (1994-05-01), None
patent: WO 96/23068 (1996-08-01), None
patent: WO 98/02151 (1998-01-01), None
patent: WO 98/11073 (1998-03-01), None
patent: WO 99/00510 (1999-01-01), None
patent: WO 99/09178 (1999-02-01), None
patent: WO 99/27122 (1999-06-01), None
patent: WO 99/36562 (1999-07-01), None
patent: WO 99/36568 (1999-07-01), None
patent: WO 99/64172 (1999-12-01), None
patent: WO 00/00491 (2000-01-01), None
patent: WO 00/06203 (2000-02-01), None
patent: WO 00/11950 (2000-03-01), None
patent: WO 00/34494 (2000-06-01), None
patent: WO 02/17900 (2002-03-01), None
patent: WO 02/17969 (2002-03-01), None
patent: WO 02/18954 (2002-03-01), None
Manning et al (Journal of Virological Methods 73:31-39, 1998).*
Ward, Stephen G., et al.; Chemokines and T Lymphocytes: More than an Attraction;Immunity; Jul. 1998; pp. 1-11; vol. 9.
Ziegler, Heike, et al.; A mouse Cytomegalovirus Glycoprotein Retains MHC Class I Complexes in the ERGIC/cis-Golgi Compartments;Immunity; Jan. 1997; pp. 57-66; vol. 6.
Beisser, Patrick S., et al.; The R33 G Protein-Coupled Receptor Gene of Rat Cytomegalovirus Plays an Essential Role in the Pathogenesis of Viral Infection;Journal of Virology; Mar. 1998; pp. 2352-2363; vol. 72, No. 3.
Beisser, Patrick S., et al.; Deletion of the R78 G Protein-Coupled Receptor Gene from Rat Cytomegalovirus Results in an Attenuated, Syncytium-inducing Mutant Strain;Journal of Virology; Sep. 1999; pp. 7218-7230; vol. 73, No. 9.
Beisser, P.S., et al.; Viral Chemokine Receptors and Chemokines in Human Cytomegalovirus Trafficking and Interaction with the Immune System;Current Topics in Microbiology and Immunology; 2002; pp. 203-234; vol. 269; Springer; Berlin, DE; XP008009472.
Billstrom, Marcella A. et al.; Intracellular Signaling by the Chemokine Receptor US28 during Human Cytomegalovirus Infection;Journal of Virology; Jul. 1998; pp. 5535-5544; vol. 72, No. 7.
Bodaghi, Bahram, et al.; Chemokine Sequestration by Viral Chemoreceptors as a Novel Viral Escape Strategy: Withdrawal of Chemokines from the Environment of Cytomegalovirus-infected Cells;J. Exp. Med.; Sep. 7, 1998, pp. 855-866; vol. 188, No. 5.
Borst, M.E., et al.; Development of a cytomegalovirus vector for somatic gene therapy;Bone Marrow Transplantation; 2000; pp. S80-S82; Supp. 2.
Cha, Tai-An, et al.; Human Cytomegalovirus Clinical Isolates Carry at Least 19 Genes Not Found in Laboratory Strains;Journal of Virology; Jan. 1996; pp. 78-83; vol. 70, No. 1.
Chee, M.S., et al.; Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169;Current Topics in Microbiology and Immunology; 1990; pp. 126-169; vol. 154.
Chee, M.S. et al.; Human cytomegalovirus encodes three G protein-coupled receptor homologues;Nature; Apr. 19, 1990; pp. 774-777; vol. 334.
Craigen, J.L., et al.; Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration;Immunology; 1997; pp. 138-145; vol. 92.
Davis-Poynter, Nicholas J., et al.; Masters of deception: A review of herpesvirus immune evasion strategies;Immunology and Cell Biology; 1996; pp. 513-522; vol. 74.
Davis-Poynter, Nicholas J., et al.; Identification and Characterization of a G Protein-Coupled Receptor Homolog Encoded by Murine Cytomegalovirus;Journal of Virology; Feb. 1997; pp. 1521-1529; vol. 71, No. 2.
Farrell, H.E., et al.; Inhibi
Penfold Mark E. T.
Schall Thomas J.
ChemoCentryx, Inc.
Mosher Mary E.
Townsend and Townsend / and Crew LLP
LandOfFree
Methods and compositions useful for stimulating an immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions useful for stimulating an immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions useful for stimulating an immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3251076